Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment

NCT06109233 is registered in ClinicalTrials.gov with FengYan Jin as lead sponsor.

NCT NCT06109233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06109233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
Lead sponsor
FengYan Jin
Phase
Observational
Overall status
Unknown status
Start date
January 10, 2022
Completion date
January 10, 2026
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

minimal residual disease, multiple myeloma